OakChart

Protagonist Therapeutics Inc

PTGXHealthcare·Biotechnology·USA·Mid·NASD·Nov 11 • 3:59 PM ET

134.86-1.40 (-1.03%)
2026-11-12 05:14 CET
Market cap
8,802.33 USD m
Revenue, TTM
551.69 USD m
Net income, TTM
342.26 USD m
Free cash flow, TTM
109.15 USD m
EPS diluted, TTM
4.72
P/E
28.57
Compare

Price

PTGX against its 20, 50 and 200-day averages
2050200beat
80.00100.00120.00140.00160.001.3M2.6MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26PTGXclose 134.8620-day 138.1950-day 140.89200-day 118.77134.8652w high52w low

16.1% under the 52-week high of 160.81 on 19 Aug 2026. 52-week low 77.00 on 23 Feb 2026. Last 15 sessions, 14.4% high to low

Volume 0.51× normal · the line is the 50-bar volume average

Profile

PTGX
52-week range, 69% of the way up
77.00160.81

Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, which engages in discovering and developing peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline includes PTG-300, PTG-200, and PN-943. The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.

IndexRUT
Employees132
IPOAug 11, 2016
Beta1.23
ATR, 14d5.72
Rel volume0.51
Short float16.59%
Insider own5.39%
Inst own115.80%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap8.80B
Enterprise Value8.01B
Income342.26M
Sales551.69M
Book/sh16.64
Cash/sh12.26
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees132
IPOAug 11, 2016

Ratios

P/E28.57
Forward P/E-
PEG-
P/S15.96
P/B8.11
P/C11.00
P/FCF80.64
EV/EBITDA24.67
EV/Sales14.52
Quick Ratio19.85
Current Ratio19.85
Debt/Eq0.01
LT Debt/Eq0.01
Option/ShortYes / Yes

Earnings

EPS (ttm)4.72
EPS next Y-0.04
EPS next Q-0.15
EPS this Y350.86%
EPS next Y-100.79%
EPS next 5Y-
EPS past 3/5Y7.63% -1.26%
Sales past 3/5Y20.07% 9.96%
EPS Y/Y TTM574.89%
Sales Y/Y TTM163.69%
EPS Q/Q597.20%
Sales Q/Q5723.64%
EarningsNov 05 AMC
EPS/Sales Surpr.0.20% 10.04%

Ownership

Insider Own5.39%
Insider Trans-11.22%
Inst Own115.80%
Inst Trans-6.16%
ROA37.04%
ROE39.56%
ROIC31.37%
Gross Margin99.51%
Oper. Margin58.56%
Profit Margin62.04%
SMA20-2.41%
SMA50-4.28%
SMA20013.55%
Trades-

Technical

Shs Outstand65.22M
Shs Float61.75M
Short Float16.59%
Short Ratio15.60
Short Interest10.24M
52W High160.81 -16.14%
52W Low77.00 75.14%
Volatility4.91% 4.17%
ATR (14)5.72
RSI (14)43.79
Beta1.23
Rel Volume0.51
Avg Volume656.36K
Volume332,659

Performance

Perf Week-5.94%
Perf Month-2.62%
Perf Quarter-10.94%
Perf Half Y29.82%
Perf YTD54.41%
Perf Year57.62%
Perf 3Y770.63%
Perf 5Y272.03%
Perf 10Y454.98%
Recom1.07
Target Price181.73
Prev Close136.26
Price134.86
Change %-1.03%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Oct 12, 2026InitiatedUUBSBuy$184+36.4%
Aug 10, 2026UpgradeGGoldmanNeutral → Buy$186+37.9%
May 21, 2026InitiatedWWolfe ResearchOutperform$135+0.1%
Sep 17, 2025InitiatedBBarclaysOverweight$72-46.6%
Sep 12, 2025InitiatedLLeerink PartnersOutperform$73-45.9%
Jun 17, 2025InitiatedCCitigroupBuy$72-46.6%
Dec 06, 2024InitiatedGGoldmanNeutral$47-65.1%
Dec 06, 2024InitiatedBBMO Capital MarketsOutperform$62-54.0%
Nov 05, 2024InitiatedWWedbushOutperform$58-57.0%
Sep 24, 2024InitiatedTTD CowenBuy$65-51.8%

Peers

Mkt cap
TickerCompanyMkt cap
ORKAOruka Therapeutics Inc7.27B
INCYIncyte Corp24.92B
IRONDisc Medicine Inc3.97B
ALMSAlumis Inc883.74M
KYMRKymera Therapeutics Inc11.51B
SLNSilence Therapeutics Plc ADR1.23B
MLTXMoonLake Immunotherapeutics1.15B
SYRESpyre Therapeutics Inc10.14B
JNJJohnson & Johnson675.03B
TAKTakeda Pharmaceutical Co ADR66.58B

Insider trading

latest 14 of 82
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Ali AsifChief Financial OfficerSep 30 '26Option Exercise23.7258,6291,390,735117,632Oct 02 04:10 PM
Ali AsifChief Financial OfficerSep 30 '26Sale141.7858,6298,312,29459,003Oct 02 04:10 PM
ASIF ALIOfficerSep 30 '26Proposed Sale140.9758,6298,264,930Sep 30 04:20 PM
PATEL DINESH V PH DPresident and CEOSep 09 '26Option Exercise21.5863,5481,371,366586,516Sep 10 09:17 PM
PATEL DINESH V PH DPresident and CEOSep 08 '26Option Exercise21.5854,1741,169,075577,142Sep 10 09:17 PM
PATEL DINESH V PH DPresident and CEOSep 10 '26Option Exercise21.587,278157,059530,246Sep 10 09:17 PM
PATEL DINESH V PH DPresident and CEOSep 09 '26Sale146.1863,5489,289,447522,968Sep 10 09:17 PM
PATEL DINESH V PH DPresident and CEOSep 08 '26Sale145.8754,1747,902,361522,968Sep 10 09:17 PM
PATEL DINESH V PH DPresident and CEOSep 10 '26Sale144.107,2781,048,760522,968Sep 10 09:17 PM
PATEL DINESH V PH DPresident and CEOAug 10 '26Option Exercise21.5865,7611,419,122589,239Aug 12 06:43 PM
PATEL DINESH V PH DPresident and CEOAug 11 '26Option Exercise21.5834,239738,878557,717Aug 12 06:43 PM
PATEL DINESH V PH DPresident and CEOAug 10 '26Sale149.1165,7619,805,623523,478Aug 12 06:43 PM
PATEL DINESH V PH DPresident and CEOAug 11 '26Sale148.5234,2395,085,176523,478Aug 12 06:43 PM
Dinesh PatelCEOAug 10 '26Proposed Sale149.26225,00033,583,500Aug 10 04:49 PM

Held by

AUM
TickerCompanyAUM
IJRiShares Core S&P Small-Cap ETFAUM: 106.27B
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VBVanguard Morningstar Small-Cap ETFAUM: 79.59B
XBIState Street SPDR S&P Biotech ETFAUM: 10.50B
VBKVanguard Morningstar Small-Cap Growth ETFAUM: 22.34B
VXFVanguard Extended Market Index ETFAUM: 30.47B
SPSMState Street SPDR Portfolio S&P 600TM Small Cap ETFAUM: 16.06B
XSMOInvesco S&P SmallCap Momentum ETFAUM: 2.74B
IJTiShares S&P Small-Cap 600 Growth ETFAUM: 7.45B

News

latest 14 of 200

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-053.0703.0643.070274.41249.3813
2026Q22026-08-052.2902.2132.293213.48198.6610
2026Q12026-05-050.050-0.5000.05456.3711.7013
2025Q42026-02-26-0.690-0.567-0.6937.448.7413
2025Q32025-11-06-0.620-0.627-0.6174.713.5813
2025Q22025-08-06-0.550-0.579-0.5485.557.5112
2025Q12025-04-30-0.189-0.204-0.18528.2637.5010
2024Q42025-02-211.9801.1521.983170.64117.7611
2024Q32024-11-07-0.540-0.578-0.5384.683.118
2024Q22024-08-06-0.500-0.595-0.4994.173.146
2024Q12024-05-083.2603.3673.260254.95262.56
2023Q42024-02-280.4400.0540.44260.0060.006
2023Q32023-11-02-0.580-0.661-0.5760.000.006
2023Q22023-08-03-0.680-0.666-0.6770.000.006
2023Q12023-05-04-0.670-0.726-0.6670.002.006
2022Q42023-03-15-0.690-0.668-0.6940.003.336

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-2.980-2.948-2.9810.231.74
2020FY-1.920-1.936-1.92328.6325.69
2021FY-2.710-2.714-2.71027.3623.20
2022FY-2.600-2.570-2.59826.5829.85
2023FY-1.390-1.622-1.39160.0060.00
2024FY4.2303.4534.229434.43382.04
2025FY-2.050-1.965-2.05046.0247.04
2026FY-5.143--564.46
2027FY--0.041--223.34
2028FY-2.503--427.56
2029FY-5.893--735.68
2030FY-8.242--966.8

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-10136345.422.70167.9
2026Q4S2026-11-09136345.412.70167.9
2026Q4S2026-11-06137245.422.70167.9
2026Q4S2026-11-05126242.532.70162.1
2026Q4S2026-10-21123335.272.65162.1
2026Q4S2026-10-20124335.272.65162.1
2026Q4S2026-10-09124535.292.65162.1
2026Q4S2026-10-07114437.892.65162.1
2026Q4S2026-09-29115437.892.65162.1
2026Q4S2026-09-19116437.892.65162.1
2026Q4S2026-08-31117437.892.65162.1
2026Q4S2026-08-28117437.702.65162.1
2026Q4S2026-08-27118347.932.65197.87
2026Q4S2026-08-14117447.732.65197.87

Estimate history

EPS, annual-2.09-1.74-2.981-1.923-2.71-2.598-1.3914.229-2.0474.7211
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.5381.983-0.185-0.548-0.617-0.6930.0542.2933.067
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual20.06330.9250.23128.62827.35726.58160434.43346.016551.69
Period201720182019202020212022202320242025TTM
Sales, quarterly4.675170.63828.3215.5464.7127.43756.368213.475274.41
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual21.08823.18727.21843.74547.83849.33957.70961.03562.57865.216
Period201720182019202020212022202320242025MRQ
Shares, quarterly59.52261.03561.92962.10862.44762.57864.22764.67265.216
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue551.6946.02434.4360.0026.5827.3628.630.2330.93
Cost of Goods Sold Incl. D&A2.691.232.963.311.032.77---
Gross Profit549.0044.79431.4756.6925.5524.58---
Selling, General and Administrative Excl. Other225.91202.92178.63150.34156.92153.5393.8682.7572.67
Research and Development176.43159.29138.13120.16126.22129.1176.0167.7059.50
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income323.10-158.13252.84-93.65-131.37-128.94-66.02-83.22-42.27
Interest Expense0.000.000.000.000.000.000.600.170.00
Unusual Expense0.000.000.000.000.000.000.58-0.00
Net Income Before Taxes350.25-129.31279.41-78.95-127.39-128.65-65.84-79.18-39.72
Income Taxes7.990.844.220.000.00-3.100.30-1.99-0.80
Consolidated Net Income342.26-130.15275.19-78.95-127.39-125.55-66.15-77.19-38.92
Net Income From Continuing Operations342.26-130.15275.19-78.95-127.39-125.55-66.15-77.19-38.92
Net Income342.26-130.15275.19-78.95-127.39-125.55-66.15-77.19-38.92
EPS (Recurring)4.77-2.054.23-1.39-2.60-2.71-1.91-2.98-1.74
EPS (Basic, Before Extraordinaries)5.15-2.054.47-1.39-2.60-2.71-1.92-2.98-1.74
EPS (Diluted)4.72-2.054.23-1.39-2.60-2.71-1.92-2.98-1.74
EBITDA324.68-156.90255.81-90.34-130.34-126.17-65.23-82.52-41.74
Non-Operating Income (Expense)27.1528.8226.5714.703.980.291.354.212.55
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense42.3636.3229.6729.2924.2016.395.776.106.92
Price To Earnings Ratio28.5728.5714.48------
Price To Sales Ratio18.32120.665.7821.6920.1357.9124.22790.274.87
Gross Margin99.5197.3499.3294.4896.1289.86---
Operating Margin58.56-343.6358.20-156.09-494.24-471.34-230.60-36,026.41-136.68
Net Margin62.04-282.8363.34-131.59-479.26-458.94-231.07-33,414.29-125.87
Shares Outstanding65.2262.5861.0457.7149.3447.8443.7527.2223.19
Market Capitalization8,802.338,802.332,300.481,322.56536.751,632.30848.27185.27162.09

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue274.41213.4756.377.444.715.5528.32170.64
Cost of Goods Sold Incl. D&A1.510.400.410.380.360.300.240.60
Gross Profit272.90213.0855.967.064.355.2428.08170.03
Selling, General and Administrative Excl. Other54.5754.3159.6157.4250.7747.2847.3943.25
Research and Development41.2742.0646.7446.3640.0037.0435.8934.90
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income218.33158.77-3.65-50.35-46.42-42.04-19.31126.78
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense0.000.000.000.000.000.000.000.00
Net Income Before Taxes226.57165.112.28-43.72-39.34-34.60-11.65133.66
Income Taxes6.562.27-1.500.670.000.170.001.99
Consolidated Net Income220.01162.853.78-44.38-39.34-34.77-11.65131.67
Net Income From Continuing Operations220.01162.853.78-44.38-39.34-34.77-11.65131.67
Net Income220.01162.853.78-44.38-39.34-34.77-11.65131.67
EPS (Recurring)3.072.290.05-0.69-0.62-0.55-0.191.98
EPS (Basic, Before Extraordinaries)3.322.470.06-0.69-0.62-0.55-0.192.11
EPS (Diluted)3.072.290.05-0.69-0.62-0.55-0.191.98
EBITDA218.74159.16-3.24-49.98-46.06-41.74-19.07127.38
Non-Operating Income (Expense)8.246.355.936.647.087.447.666.88
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense11.3511.0911.478.4510.568.6213.807.18
Price To Earnings Ratio28.57--137.8993.2272.6611.5014.48
Price To Sales Ratio18.3230.87100.32121.5320.2516.7814.655.90
Gross Margin99.4599.8199.2894.9492.3494.5299.1699.65
Operating Margin79.5674.37-6.47-677.09-985.17-758.04-68.1874.30
Net Margin80.1876.286.71-596.80-834.87-626.96-41.1577.17
Shares Outstanding65.2264.6764.2362.5862.4562.1161.9361.04
Market Capitalization8,802.337,883.296,725.445,460.124,132.703,425.752,968.542,300.48

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments567.36418.91341.62237.35326.90305.82133.03128.86144.01
Short Term Receivables4.50168.4910.330.055.333.827.506.513.22
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets5.714.243.635.678.505.974.792.133.71
Total Current Assets577.57591.64355.58243.08340.74315.61145.31137.50150.95
Net Property, Plant & Equipment11.6912.612.154.636.736.417.720.860.88
Total Investments and Advances78.92140.480.230.230.232.450.450.4511.91
Intangible Assets0.000.000.000.000.000.000.000.000.00
Deferred Tax Assets1.712.100.22--1.042.700.66-
Other Assets0.000.000.000.000.000.000.000.000.00
Total Assets669.89746.83358.17247.93347.69325.51156.19139.47163.73
Short Term Debt Incl. Current Port. of LT Debt2.280.511.142.522.201.461.260.000.00
Accounts Payable5.341.610.783.712.505.814.055.711.26
Income Tax Payable0.002.69-------
Other Current Liabilities37.8242.5819.3624.9539.3232.9830.1020.4541.30
Total Current Liabilities45.4447.4021.2731.1844.0240.2435.4126.1642.55
Long Term Debt8.0410.360.001.143.664.5015.760.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Deferred Tax Liabilities1.712.100.22--1.041.27--
Other Liabilities0.0011.680.000.000.000.1223.790.800.55
Total Liabilities55.1971.5321.5032.3247.6745.9076.2226.9643.10
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity614.71675.29336.68215.61300.02279.6179.96112.52120.63
Total Shareholders Equity614.71675.29336.68215.61300.02279.6179.96112.52120.63
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity614.71675.29336.68215.61300.02279.6179.96112.52120.63
Total Liabilities & Stockholders Equity669.89746.83358.17247.93347.69325.51156.19139.47163.73
Book Value Per Share9.8211.065.834.376.276.392.944.855.72
Tangible Book Value Per Share9.8211.065.834.376.276.392.944.855.72
Full-Time Employees13212611210511879736455
Price to Book Ratio8.114.324.372.205.453.152.401.396.09
Return on Assets-18.3749.81-26.05-42.78-37.30-27.47-52.21-25.67-28.68
Return on Equity-20.1854.39-28.59-49.41-43.32-36.79-80.20-33.39-35.50
Return on Invested Capital-20.9040.14-23.45-58.77-41.34-23.28-80.64-34.59-30.64
Quick Ratio12.7112.4816.717.807.747.844.105.263.55
Current Ratio12.7112.4816.717.807.747.844.105.263.55

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income342.26-130.15275.19-78.95-127.39-125.55-66.15-77.19-38.92
Depreciation1.591.282.903.311.032.770.790.700.53
Other Funds (Non Cash)50.7940.3328.6824.9225.9918.2310.449.597.12
Funds from Operations394.64-88.54306.76-50.73-100.37-104.55-53.48-67.67-31.93
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-284.73146.21-122.61-19.51-7.77-3.31-19.0226.14-18.02
Income Taxes Payable4.22-2.692.69------
Cash from Operating Activities109.9157.67184.15-70.24-108.14-107.86-72.50-41.53-49.95
Capital Expenditures-0.76-1.59-1.35-0.61-0.80-1.10-0.47-0.97-0.49
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00-
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.00-
Purchase or Sale of Investments231.47-47.74-298.13-38.6592.26-14.76-90.49-52.742.70
Purchase of Investments-316.87-546.59-621.70-191.04-214.87-286.59-280.03-166.94-71.06
Sale Or Maturity of Investments548.34498.84323.57152.40307.14271.83189.53114.1973.76
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.000.00
Cash from Investing Activities230.71-49.33-299.48-39.2691.47-15.86-90.97-53.712.21
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock43.9623.3426.45171.2519.03130.11258.1636.2724.11
Repurchase of Common Pref Stock-5.790.000.000.000.000.000.000.000.00
Sale of Common Pref Stock49.7523.3426.45171.2519.03130.11258.1636.2724.11
Proceedsfrom Stock Options0.000.000.00132.1014.58123.83255.3734.4923.18
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00-10.529.770.00
Change in Long Term Debt0.000.000.000.000.000.00-10.529.770.00
Issuance of Long Term Debt0.000.000.000.000.000.000.009.770.00
Reduction of Long Term Debt0.000.000.000.000.000.00-10.520.000.00
Net Financing Active Other Cash Flow0.00-0.48-0.60-0.77-0.19-0.190.000.000.00
Other Financing Activities Uses0.00-0.48-0.60-0.77-0.19-0.190.000.000.00
Cash from Financing Activities43.9622.8625.85170.4818.84129.92247.6446.0424.11
Exchange Rate Effect--0.000.00-0.09-0.130.17-0.03-0.18
Net Change in Cash384.5831.20-89.4860.982.086.0784.35-49.23-23.80
Free Cash Flow109.1556.08182.80-70.84-108.93-108.97-72.97-42.49-50.43
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Price to Free Cash Flow92.5999.0113.74------
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.001.44-0.78-0.66

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments800.06782.58547.79567.36576.12570.47
Short Term Receivables290.9119.6457.124.505.3327.97
Inventories0.000.000.000.000.000.00
Other Current Assets10.094.938.555.714.984.09
Total Current Assets1,101.06807.15613.46577.57586.42602.53
Net Property, Plant & Equipment9.8210.4011.1711.6912.2712.70
Total Investments and Advances34.8467.1672.8478.92102.99102.78
Intangible Assets--0.000.000.000.00
Deferred Tax Assets---1.71--
Other Assets0.830.830.000.000.000.00
Total Assets1,146.55885.54697.46669.89701.69718.01
Short Term Debt Incl. Current Port. of LT Debt2.452.402.342.282.232.17
Accounts Payable5.923.468.445.345.653.25
Income Tax Payable4.22--0.000.000.00
Other Current Liabilities42.8731.3323.7737.8237.0730.09
Total Current Liabilities55.4637.1834.5545.4444.9435.51
Long Term Debt6.186.827.448.048.529.11
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities---1.71--
Other Liabilities0.000.000.000.002.795.38
Total Liabilities61.6444.0041.9955.1956.2549.99
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity1,084.91841.54655.47614.71645.44668.02
Total Shareholders Equity1,084.91841.54655.47614.71645.44668.02
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity1,084.91841.54655.47614.71645.44668.02
Total Liabilities & Stockholders Equity1,146.55885.54697.46669.89701.69718.01
Book Value Per Share16.6413.0110.219.8210.3410.76
Tangible Book Value Per Share16.6413.0110.219.8210.3410.76
Full-Time Employees-141131132128130
Price to Book Ratio8.1112.0110.738.456.184.97
Return on Assets37.0410.34-15.94-18.377.037.81
Return on Equity39.5610.98-17.06-20.187.808.61
Return on Invested Capital20.1619.200.57-7.13-6.02-5.14
Quick Ratio19.8521.7117.7612.7113.0516.97
Current Ratio19.8521.7117.7612.7113.0516.97

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income220.01162.853.78-44.38-39.34-34.77
Depreciation0.410.400.410.380.360.30
Other Funds (Non Cash)13.7213.4313.939.708.989.57
Funds from Operations234.15176.6818.12-34.31-30.00-24.90
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-257.3742.37-67.06-2.6728.06-3.88
Income Taxes Payable4.220.000.000.000.00-1.89
Cash from Operating Activities-23.22219.05-48.94-36.98-1.94-28.78
Capital Expenditures-0.24-0.17-0.21-0.14-0.09-0.81
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments93.67-2.2691.1148.96-58.4755.62
Purchase of Investments-8.95-134.68-68.97-104.27-161.12-67.15
Sale Or Maturity of Investments102.62132.41160.07153.23102.65122.78
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities93.43-2.4390.8948.81-58.5554.81
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock8.019.7423.372.845.662.92
Repurchase of Common Pref Stock-5.790.000.000.000.000.00
Sale of Common Pref Stock13.809.7423.372.845.662.92
Proceedsfrom Stock Options0.000.000.000.000.000.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities8.019.7423.372.845.662.92
Net Change in Cash78.22226.3765.3214.68-54.8328.95
Free Cash Flow-23.46218.88-49.16-37.12-2.02-29.59
Price to Free Cash Flow92.5966.66-99.7266.4994.62

Revenue breakdown

Pharmaceutical Preparations2024: 434.43M 2025: 46.02M
United States2024: 434.43M 2025: 46.02M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3016.73%10.2M61.2M643.09K
2026-10-1516.82%10.3M61.2M629.46K
2026-09-3015.27%9.3M61.2M627.37K
2026-09-1513.30%8.1M61.2M663.75K
2026-08-3112.60%7.7M61.2M684.52K
2026-08-1412.73%7.8M61.2M679.01K
2026-07-3112.28%7.5M61.4M694.60K
2026-07-1513.59%8.3M61.0M715.64K
2026-06-3012.60%7.7M61.0M695.69K
2026-06-1512.67%7.7M61.0M717.51K
2026-05-2912.15%7.4M61.0M730.38K
2026-05-1512.01%7.3M60.8M746.55K
2026-04-3012.45%7.5M60.6M759.70K
2026-04-1514.00%8.4M60.0M784.04K
2026-03-3114.38%8.6M60.0M822.22K
2026-03-1313.44%8.1M60.0M752.22K
2026-02-2713.66%8.2M60.0M804.94K
2026-02-1314.40%8.4M58.7M852.72K
2026-01-3013.79%8.1M59.0M904.35K
2026-01-1514.07%8.3M59.0M943.26K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call90.0042.6047.500.002.3130.000.000.898-0.5180.037
call95.0037.6042.500.002.0760.000.000.887-0.5010.040
call10032.6037.400.001.9430.000.000.875-0.4830.043
call10527.5032.300.001.6060.000.000.830-0.6170.053
call11022.5027.3018.601.3932.000.000.810-0.5840.057
call11517.7022.5027.501.2032.000.000.784-0.5460.061
call12012.5017.3023.751.0441.000.000.752-0.5000.066
call1258.0012.800.000.8990.000.000.710-0.4340.072
call1304.008.8010.500.72810.000.000.644-0.3580.078
call1351.156.003.610.71835.000.000.522-0.3460.084
call1400.004.902.550.83633.000.000.408-0.3710.081
call1450.004.902.001.06258.000.000.351-0.4590.078
call1500.001.503.500.73714.000.000.185-0.2320.057
call1550.004.902.100.8683.000.000.165-0.2550.052
call1600.004.900.550.98528.000.000.150-0.2740.049
call1650.004.901.001.06811.000.000.139-0.2800.047
call1700.004.900.001.2170.000.000.127-0.2960.044
call1750.004.900.001.3100.000.000.121-0.3140.042
call1800.004.900.001.3740.000.000.115-0.3140.041
call1850.004.902.971.4661.000.000.109-0.3230.040
call1900.004.900.001.5540.000.000.104-0.3320.039
call1950.004.900.001.6380.000.000.100-0.3400.038
call2000.004.900.001.7190.000.000.097-0.3470.037
put90.000.004.900.002.3550.000.00-0.104-0.4920.038
put95.000.004.900.202.1601.000.00-0.113-0.4890.040
put1000.002.900.001.5280.000.00-0.086-0.2720.035
put1050.004.900.002.0270.000.00-0.170-0.6060.053
put1100.004.900.001.7830.000.00-0.190-0.5720.057
put1150.004.900.001.5450.000.00-0.216-0.5330.061
put1200.004.900.001.2800.000.00-0.253-0.4780.067
put1250.004.902.251.0341110.00-0.296-0.4030.072
put1300.004.504.500.82315.000.00-0.353-0.3430.078
put1351.156.005.250.71745.000.00-0.478-0.3310.084
put1404.008.8012.000.70010.000.00-0.592-0.3560.081
put1458.0012.8014.400.69510.000.00-0.649-0.4270.078
put15013.0017.8010.900.8565.000.00-0.811-0.2190.057
put15517.5022.3025.901.0021.000.00-0.834-0.2390.052
put16022.5027.3031.001.1363.000.00-0.850-0.2560.049
put16527.5032.300.001.2610.000.00-0.862-0.2710.046
put17032.5037.400.001.3780.000.00-0.872-0.2830.044
put17537.5042.400.001.5080.000.00-0.879-0.2940.042
put18042.5047.400.001.6140.000.00-0.886-0.3040.041
put18547.5052.400.001.7150.000.00-0.891-0.3130.039
put19052.5057.400.001.7900.000.00-0.896-0.3210.038
put19557.5062.400.001.9030.000.00-0.900-0.3290.037
put20062.5067.400.001.9700.000.00-0.904-0.3360.036

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-0610-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-058-KCurrent report2026-11-05SEC
2026-10-27SCHEDULE 13G/ASEC
2026-10-024Statement of changes in beneficial ownership of securities2026-09-30SEC
2026-09-30144Filing for proposed sale of securities under Rule 144.SEC
2026-09-104Statement of changes in beneficial ownership of securities2026-09-08SEC
2026-09-084Statement of changes in beneficial ownership of securities2026-09-03SEC
2026-08-13SCHEDULE 13G/ASEC
2026-08-124Statement of changes in beneficial ownership of securities2026-08-10SEC
2026-08-10144Filing for proposed sale of securities under Rule 144.SEC
2026-08-07SCHEDULE 13GSEC
2026-08-05S-8 POSPost-effective amendment to a S-8 registration statementSEC
2026-08-05S-8 POSPost-effective amendment to a S-8 registration statementSEC
2026-08-05S-8 POSPost-effective amendment to a S-8 registration statementSEC
2026-08-05S-8 POSPost-effective amendment to a S-8 registration statementSEC
2026-08-05S-8 POSPost-effective amendment to a S-8 registration statementSEC
2026-08-05S-8 POSPost-effective amendment to a S-8 registration statementSEC
2026-08-05S-8 POSPost-effective amendment to a S-8 registration statementSEC
2026-08-05S-8 POSPost-effective amendment to a S-8 registration statementSEC
2026-08-05S-8 POSPost-effective amendment to a S-8 registration statementSEC
2026-08-05S-8 POSPost-effective amendment to a S-8 registration statementSEC
2026-08-05S-8 POSPost-effective amendment to a S-8 registration statementSEC
2026-08-05S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-08-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-058-KCurrent report2026-08-05SEC
2026-06-254Statement of changes in beneficial ownership of securities2026-06-23SEC
2026-06-23144Filing for proposed sale of securities under Rule 144.SEC
2026-06-188-KCurrent report2026-06-17SEC
2026-06-114Statement of changes in beneficial ownership of securities2026-06-10SEC
2026-06-10144Filing for proposed sale of securities under Rule 144.SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090026.55M4
2026-080014.89M2
2026-070000
2026-06002.03M2
2026-050014.32M6
2026-0400184.57K1
2026-030012.20M5
2026-02003.16M2
2026-010014.14M10
2025-120000
2025-1100229.90K1

Institutional holders

Manager% owned
BlackRock, Inc.16.03%
FARALLON CAPITAL MANAGEMENT, L.L.C.9.87%
RTW INVESTMENTS, LP7.87%
UBS Group AG6.11%
VANGUARD PORTFOLIO MANAGEMENT LLC5.64%
WELLINGTON MANAGEMENT GROUP LLP5.31%
STATE STREET CORP5.16%
VANGUARD CAPITAL MANAGEMENT LLC4.44%
JOHNSON & JOHNSON3.78%
Invesco Ltd.3.64%

Funds

Fund% owned
iShares Core S&P Small-Cap ETF5.66%
VANGUARD TOTAL STOCK MARKET INDEX FUND3.18%
iShares Russell 2000 ETF2.46%
VANGUARD SMALL-CAP INDEX FUND2.29%
VANGUARD HEALTH CARE FUND1.93%
State Street(R) SPDR(R) S&P(R) Biotech ETF1.46%
VANGUARD EXPLORER FUND1.37%
VANGUARD SMALL-CAP GROWTH INDEX FUND1.32%
T. Rowe Price Health Sciences Fund, Inc.1.29%
Invesco Discovery Fund1.25%

OakChart. PTGX. Cached 15 minutes.